No recommendation for Novo Nordisk's much-anticipated weight loss therapy

The Pharmaceutical Benefits Advisory Committee has pointed to the "extremely high cost" as a reason for rejecting a much-anticipated weight-loss therapy. It has also provided advice on extending access to more PBS medicines for people in custodial settings. …